Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cintas Corporation (CTAS) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Cintas CorporationTrade
DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

Cintas Corporation vs DENTSPLY SIRONA Inc — how do they compare? Cintas Corporation trades at $200.75 (market cap $79.86B), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.73B). The key difference: Cintas Corporation is far larger — about 46.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and DENTSPLY SIRONA Inc for 72 Days on average.

CTASXRAY
Market Cap
$79.86B$1.73B
Volume
1,323,5836,198,582
Sector
IndustrialsHealth
52-Week High
$216.53$14.68
52-Week Low
$163.55$8.52
Typical Hold Time
124 Days72 Days
Enterprise Value
$82.33B$3.80B
Dividend Yield
1.03%5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cintas Corporation

Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2027 results with revenue of $3.01 billion, beating estimates, and raised full-year guidance. Fundamentals show robust revenue growth, expanding margins, and high profitability, though valuation multiples like a P/E of 39.67 are elevated. Analyst sentiment is moderately bullish with a consensus price target of $234.60.

The outlook for CTAS is positive, driven by durable growth, record margins, and strong capital returns. Key opportunities include consistent earnings beats and market leadership, while risks involve high valuation sensitivity and competitive pressures. The stock's upside potential is supported by analyst targets, but investors should monitor execution against guidance.

DENTSPLY SIRONA Inc

DENTSPLY SIRONA (XRAY) trades at $8.54, near a 52-week low, with a bearish technical signal from moving averages. The company reported a Q2 2026 earnings beat but faces declining revenues and negative net income margins. Recent news highlights institutional stake increases and ongoing turnaround efforts amid sales weakness in dental segments.

The outlook remains challenging due to persistent profitability issues and high debt, though analyst consensus suggests upside to a $13.40 price target. Key risks include margin pressure and competitive threats, while potential catalysts include successful restructuring and digital dentistry growth.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CTAS
100% Buy0% Sell
Avg holding period · 124 Days
XRAY

No sentiment data available yet.

Top news

Latest headlines on both assets

About Cintas Corporation

In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).

Read more on CTAS →

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY →